157 E 32nd St. New York, NY 10016 212-689-6791


Welcome to the PD-1 Immunotherapy trial at MHOA

Now enrolling patients for a PD-1 Immunotherapy trial at MHOA in New York City

This study will investigate Pembrolizimab plus Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone for patients not eligible for treatment with stem cell transplantation.

For more information about this Multiple Myeloma clinical trial, click here.

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com


Now enrolling of patients on a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are….

Read More


Now enrolling patients for a phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215)…

Read More

Mantle Cell Lymphoma

Now enrolling patients in a phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of…

Read More


Now enrolling patients for the InformCLL Registry, which is to characterize and describe treatment patterns for those initiating treatment with…

Read More